Drug Interaction Report

MONITOR: Sirolimus may be systemically absorbed following topical administration and in some patients may have systemic immunosuppressive effects. Theoretically, administration of vaccines during treatment with topical sirolimus may result in a diminished or suboptimal immunologic response to the vaccine. No formal studies have been conducted to evaluate the response to vaccination during treatment with topical sirolimus.

MANAGEMENT: All age-appropriate vaccinations should be completed as recommended by current immunization guidelines prior to initiating treatment with topical sirolimus. In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines and prescribing information for individual vaccines should be consulted.

MONITOR: Sirolimus may be systemically absorbed following topical administration and in some patients may have systemic immunosuppressive effects. Theoretically, administration of vaccines during treatment with topical sirolimus may result in a diminished or suboptimal immunologic response to the vaccine. No formal studies have been conducted to evaluate the response to vaccination during treatment with topical sirolimus.

MANAGEMENT: All age-appropriate vaccinations should be completed as recommended by current immunization guidelines prior to initiating treatment with topical sirolimus. In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines and prescribing information for individual vaccines should be consulted.

MONITOR: Sirolimus may be systemically absorbed following topical administration and in some patients may have systemic immunosuppressive effects. Theoretically, administration of vaccines during treatment with topical sirolimus may result in a diminished or suboptimal immunologic response to the vaccine. No formal studies have been conducted to evaluate the response to vaccination during treatment with topical sirolimus.

MANAGEMENT: All age-appropriate vaccinations should be completed as recommended by current immunization guidelines prior to initiating treatment with topical sirolimus. In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines and prescribing information for individual vaccines should be consulted.